Ascendis Pharma A (ASND) Equity Average (2013 - 2022)
Ascendis Pharma A's (ASND) quarterly Equity Average came in at $362.0 million in Q4 2022, down 34.42% quarter-over-quarter from $551.9 million in Q3 2022.
Ascendis Pharma A (ASND) Equity Average (2013 - 2022) Analysis & Trends
Ascendis Pharma A has disclosed Equity Average across 3 years of filings, most recently posting $362.0 million for Q4 2022.
- Equity Average for Q4 2022 came in at $362.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $362.0 million (changed N/A YoY), and the FY2025 annual result was -$151.2 million, down 12.15% from the prior year.
- Equity Average came in at $362.0 million for Q4 2022 at Ascendis Pharma A, down from $551.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $984.2 million in Q1 2021 to a low of $362.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Ascendis Pharma A | 2.75 Bn | 2.08 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 361.98 Mn |
| Sep 30, 2022 | 551.95 Mn |
| Jun 30, 2021 | 898.16 Mn |
| Mar 31, 2021 | 984.19 Mn |
| Dec 31, 2013 | 5.30 Mn |